drugset / Trial / NCT07326878
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
Phase 1
Not yet recruiting
144 enrolled
Institute of Medical Biology, Chinese Academy of Medical Sciences
The Second Affiliated Hospital of Chongqing Medical University · collab
RandomizedSequentialDouble-blindPrevention
Summary
This is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6 months to 59 years ).
Timeline
- Start
- 2025-12-30
- Primary completion
- 2026-08-15
- Completion
- 2027-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine | Vaccine | 0.1 ml | — |